Who are HBV-MPL vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fendrix vaccine, HBV-MPL vaccine (208129).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hbv-mpl-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HBV-MPL vaccine — Competitive Intelligence Brief

HBV-MPL vaccine (HBV-MPL vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant hepatitis B vaccine with adjuvant. Area: Immunology / Infectious Disease.

phase 3 Recombinant hepatitis B vaccine with adjuvant Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

HBV-MPL vaccine (HBV-MPL vaccine) — GlaxoSmithKline. HBV-MPL vaccine stimulates immune response against hepatitis B virus by combining hepatitis B surface antigen with MPL (monophosphoryl lipid A), an adjuvant that enhances T-cell and B-cell activation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HBV-MPL vaccine TARGET	HBV-MPL vaccine	GlaxoSmithKline	phase 3	Recombinant hepatitis B vaccine with adjuvant	Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant)
Fendrix vaccine	Fendrix vaccine	Henogen	phase 3	Recombinant hepatitis B vaccine with adjuvant	Hepatitis B surface antigen (HBsAg)
HBV-MPL vaccine (208129)	HBV-MPL vaccine (208129)	GlaxoSmithKline	phase 3	Recombinant hepatitis B vaccine with adjuvant	Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant hepatitis B vaccine with adjuvant class)

GlaxoSmithKline · 2 drugs in this class
Henogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HBV-MPL vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hbv-mpl-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab